azacitidine and Hematologic Neoplasms

azacitidine has been researched along with Hematologic Neoplasms in 61 studies

Research

Studies (61)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	20 (32.79)	29.6817
2010's	29 (47.54)	24.3611
2020's	12 (19.67)	2.80

Authors

Authors	Studies
Asatiani, E; Berenson, JR; Bordoni, R; Cook, RJ; Edenfield, WJ; Mohan, S; Savona, MR; Srinivas, N; Zeidan, AM; Zhou, G	1
Han, S; Han, Y; Li, X; Pan, T; Qi, J; Wang, H; Xu, X; Yao, Y; Zhou, M	1
Blum, S; Bresser, H; Lübbert, M; Tsilimidos, G	1
Ciernikova, S; Fridrichova, I; Kalinkova, L; Sevcikova, A; Stevurkova, V	1
de Graaf, IJ; Heemskerk, MHM; Kroonen, JS; Kumar, S; Remst, DFG; Vertegaal, ACO; Wouters, AK	1
Dworzak, MN; Hasle, H; Hoogendijk, R; Huitema, ADR; Janssen, JM; Laille, EJ; Lopez-Yurda, M; Niemeyer, CM; Rubio-San-Simón, A; van den Heuvel-Eibrink, MM; van Eijkelenburg, NKA; van Tinteren, H; Zecca, M; Zwaan, CM	1
Aster, JC; Brooks, CL; Christie, AL; Craig, JW; Ghandi, M; Johannessen, CM; Johnson, CA; Jones, KL; Lane, AA; Letai, A; Lindsay, RW; Montero, J; Pastika, T; Pozdnyakova, O; Stephansky, J; Togami, K; Weinstock, DM	1
Gillberg, L; Grønbæk, K; Helbo, AS; Hellström-Lindberg, E; Jones, PA; Liang, G; Liu, M; Ohtani, H; Sun, W; Ungerstedt, J; Zhou, W; Ørskov, AD	1
Dutton, N; Fazal, S; Samhouri, Y; Tanvi, V; Ursu, S	1
Kiianitsa, K; Maizels, N; Zhang, Y	1
Baugh, JA; Neary, R; Russell-Hallinan, A; Watson, CJ	1
Bach, E; Franke, GN; Kayser, S; Kurch, L; Opitz, S; Platzbecker, U; Thomassen, K; Wang, SY	1
Agrawal, N; Ahmed, R; Bhurani, D; Choudhary, PS; Folbs, B; Kapoor, J; Khushoo, V; Mehta, P; Mirgh, S; Sharma, A; Tejwani, N	1
Choi, J; Cooper, ML; DiPersio, JF; Karpova, D; Ritchey, J; Schroeder, MA; Vij, K	1
Abaza, YM; Alfonso, A; Borthakur, G; Chang, JE; Chong, TH; Chuah, C; Dong, XQ; Durkes, DE; Estrov, Z; Ferrajoli, A; Foudray, MC; Garcia-Manero, G; Goh, BC; Jabbour, EJ; Kadia, TM; Kantarjian, HM; Koh, LP; Konopleva, MY; Wierda, WG	1
Allen, JE; Babar, J; Benes, CH; Claxton, DF; Dicker, DT; El-Deiry, WS; Garnett, MJ; Grupp, SA; Hall, J; Khan, N; Kline, CLB; Lulla, AR; McDermott, U; Oster, W; Prabhu, VV; Pu, JJ; Talekar, MK; Van den Heuvel, APJ; Zhou, L	1
Aoyagi, T; Daitoku, S; Kuroiwa, M; Tada, S; Takao, S	1
Cruijsen, M; Huls, G; Joosten, I; Koenen, HJPM; Landman, S; Urbano, PCM; van Erp, PEJ; van Rijssen, E	1
Bian, XN; Fan, LY; Hu, SY; Kong, LJ; Li, J; Ling, J; Liu, H; Lu, J; Xiao, PF; Yao, YH	1
Akahane, D; Azuma, K; Fujimoto, H; Furuya, N; Katagiri, S; Kobayashi, C; Nakamura, N; Ohyashiki, JH; Ohyashiki, K; Suguro, T; Umezu, T	1
Boyd, TE; Dong, Q; Laille, E; Savona, MR; Scott, BL; Skikne, B	1
Ayari, S; Chevallier, P; Delaunay, J; Gastinne, T; Guillaume, T; Le Gouill, S; Loirat, M; Mohty, M; Moreau, P; Peterlin, P; Tessoulin, B	1
Atlassi, M; Besançon, A; Denizon, N; Gaulard, P; Ghnaya, H; Laribi, K; Petrella, T; Pineau-Vincent, F	1
Beach, CL; Gabrail, NY; Goel, S; Kelly, K; Laille, E; Liu, L; Mita, AC; Songer, S	1
Honda, H; Inaba, T; Nagamachi, A	1
Galli, S; Harrison, CN; Keohane, C; McLornan, DP; Mwirigi, A; Radia, DH; Raj, K	1
Huang, Y; Rao, A	1
Sakata-Yanagimoto, M	1
Bennett, M; Fulton, N; Godley, LA; Green, M; Halpern, A; Karrison, T; Koval, G; Larson, RA; Madzo, J; Malnassy, G; Mattison, RJ; Odenike, O; Ratain, MJ; Stock, W; Yee, KW	1
Abdel-Wahab, O; Ahn, J; Armstrong, SA; Chiosis, G; Chung, YR; Dogan, A; Hricik, T; Intlekofer, A; Levine, RL; Lipson, D; Manshouri, T; McKenney, AS; Miller, VA; Nahas, M; Otto, GA; Pandey, S; Park, CY; Rampal, R; Rapaport, F; Stephens, PJ; van den Brink, MR; Verstovsek, S; Wang, K; Yelensky, R	1
Albert, DH; Ansell, P; Arellano, M; Garcia-Manero, G; Kadia, T; Kantarjian, H; Khoury, HJ; Knight, EA; McKee, MD; Munasinghe, W; Oliver, B; Qin, Q; Ricker, JL; Roberts-Rapp, L; Tibes, R; Xiong, H	1
Ciccolini, J; Colle, J; Costello, R; Fanciullino, R; Fina, F; Lacarelle, B; Mercier, C; Ouafik, L; Serdjebi, C; Venton, G	1
Colizzi, F; Dolcetti, R; Fratta, E; Montico, B; Rizzo, A; Sigalotti, L	1
Buschbeck, M; Diesch, J; Garz, AK; Götze, KS; Palau, A; Zwick, A	1
Baylin, SB; Charlet, J; Grønbæk, K; Jones, PA; Liang, G; Liu, M; Ohtani, H; Shen, H; Zhang, YW; Zhou, W; Ørskov, AD	1
Sidaway, P	1
Furukawa, Y	1
Aucott, T; Carraway, HE; Choi, SH; Dauses, T; Espinoza-Delgado, I; Fandy, TE; Gore, SD; Herman, JG; Jiemjit, A; Kerns, P; Kim, MK; Licht, J; McConnell, MJ; Murgo, A; Nasrallah, C; Odchimar-Reissig, R; Oteiza, K; Owoeye, I; Silverman, LR; Sugar, EA; Sun, Y; Yang, AS; Zhang, W	1
Avivi, L; Cytron, S; Korenstein-Ilan, A; Mashevich, M; Nagler, A	1
Chim, CS; Chung, LP; Jin, DY; Lam, WW; Li, GK; Liang, R; Loong, F; So, CC; Wong, KY	1
Cui, XY; Gao, WF; Lin, YM; Ma, XT; Wang, N; Yang, BX; Yao, XR	1
Engel, N; Rank, A	1
Bondada, S; Brandon, J; Bryson, JS; Howard, D; Liang, Y; Liu, Y; Mehta, J; Rector, K; Schook, L; Swiderski, C	1
Aozasa, K; Hoshida, Y; Nakatsuka, S; Nishii, K; Nishiu, M; Takakuwa, T; Tomita, Y; Yamaguchi, M; Yang, WI	1
Altomonte, M; Colizzi, F; Degan, M; Gattei, V; Maio, M; Pinto, A; Rupolo, M; Sigalotti, L; Zagonel, V	1
Hatano, S; Ito, E; Kinoshita, T; Li, Y; Nagai, H; Saito, H; Toshihito, O; Utsumi, M; Yuge, M	1
Leone, G; Lübbert, M; Teofili, L; Voso, MT	1
Bayar, E; Cortes, J; Faderl, S; Garcia-Manero, G; Giles, FJ; Issa, JP; Kantarjian, HM; Lyons, J; Mannari, R; Rosenfeld, CS; Thomas, D	1
Garcia-Manero, G; Giles, FJ; Hennessy, BT; Kantarjian, HM	1
Bayar, E; Fine, G; Lyons, J; McCullar, M; Rolens, R; Rosenfeld, C; Rubinfeld, J	1
Brown, R; Plumb, JA	1
Baker, SD; Carducci, MA; Gilbert, J; Gore, SD; Hartke, C; He, P; Rudek, MA; Zhao, M	1
Koeffler, HP; Matsushita, M; Seo, H; Taguchi, H; Takeuchi, S; Tsukasaki, K; Yang, Y; Yoshino, N	1
Almstedt, M; Claus, R; Lübbert, M	1
Issa, JP	1
Fenaux, P	1
Bai, S; Ghoshal, K	1
Issa, JP; Kantarjian, HM; Plimack, ER	1
Godley, LA; Kihslinger, JE	1
Gabrilove, JL	1

Reviews

22 review(s) available for azacitidine and Hematologic Neoplasms

Article	Year
Efficacy of azacitidine in preventing relapse after hematopoietic stem cell transplantation for advanced myeloid malignancies: a systematic review and meta-analysis. Expert review of hematology, 2022, Volume: 15, Issue:5 Topics: Azacitidine; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Neoplasm Recurrence, Local	2022
Role of Bcl-2 inhibition in myelodysplastic syndromes. International journal of cancer, 2023, 04-15, Volume: 152, Issue:8 Topics: Aged; Azacitidine; Hematologic Neoplasms; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Proto-Oncogene Proteins c-bcl-2	2023
Targeting DNA Methylation in Leukemia, Myelodysplastic Syndrome, and Lymphoma: A Potential Diagnostic, Prognostic, and Therapeutic Tool. International journal of molecular sciences, 2022, Dec-30, Volume: 24, Issue:1 Topics: Azacitidine; Decitabine; DNA Methylation; Epigenesis, Genetic; Hematologic Neoplasms; Humans; Leukemia; Lymphoma; Myelodysplastic Syndromes; Prognosis	2022
Tagraxofusp followed by combined azacitidine and venetoclax in blastic plasmacytoid dendritic cell neoplasm: A case report and literature review. Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 2021, Volume: 27, Issue:4 Topics: Acute Disease; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Dendritic Cells; Hematologic Neoplasms; Humans; Male; Recombinant Fusion Proteins; Skin Neoplasms; Sulfonamides	2021
-7/7q- syndrome in myeloid-lineage hematopoietic malignancies: attempts to understand this complex disease entity. Oncogene, 2015, May-07, Volume: 34, Issue:19 Topics: Antimetabolites, Antineoplastic; Azacitidine; Chromosome Deletion; Chromosomes, Human, Pair 7; Decitabine; Gene Expression Regulation, Neoplastic; Genetic Association Studies; Hematologic Neoplasms; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Myeloid Cells; Prognosis	2015
Connections between TET proteins and aberrant DNA modification in cancer. Trends in genetics : TIG, 2014, Volume: 30, Issue:10 Topics: 5-Methylcytosine; Azacitidine; Cytosine; Decitabine; Dioxygenases; DNA Methylation; DNA Modification Methylases; DNA-Binding Proteins; Hematologic Neoplasms; Humans; Isocitrate Dehydrogenase; Mixed Function Oxygenases; Molecular Targeted Therapy; Mutation; Neoplasms; Proto-Oncogene Proteins; Small Molecule Libraries	2014
[TET2 dysregulation in hematologic malignancies]. [Rinsho ketsueki] The Japanese journal of clinical hematology, 2014, Volume: 55, Issue:10 Topics: Azacitidine; Cytosine; Decitabine; Dioxygenases; DNA-Binding Proteins; Enzyme Inhibitors; Epigenesis, Genetic; Genetic Predisposition to Disease; Hematologic Neoplasms; Humans; Methylation; Molecular Targeted Therapy; Multigene Family; Mutation; Neoplasm Proteins; Proto-Oncogene Proteins	2014
Epimutational profile of hematologic malignancies as attractive target for new epigenetic therapies. Oncotarget, 2016, Aug-30, Volume: 7, Issue:35 Topics: Acetylation; Antineoplastic Agents; Azacitidine; Decitabine; DNA Methylation; Epigenesis, Genetic; Female; Hematologic Neoplasms; Histones; Humans; Lymphoma, T-Cell, Cutaneous; Male; Myelodysplastic Syndromes; Protein Domains	2016
A clinical-molecular update on azanucleoside-based therapy for the treatment of hematologic cancers. Clinical epigenetics, 2016, Volume: 8 Topics: Antimetabolites, Antineoplastic; Azacitidine; Clinical Trials as Topic; Decitabine; DNA Methylation; Drug Resistance, Neoplasm; Epigenesis, Genetic; Hematologic Neoplasms; Humans; Treatment Outcome	2016
[Epigenetics in hematological disorders]. [Rinsho ketsueki] The Japanese journal of clinical hematology, 2008, Volume: 49, Issue:10 Topics: Antineoplastic Agents; Azacitidine; Depsipeptides; DNA Methylation; Drug Design; Enzyme Inhibitors; Epigenesis, Genetic; Gene Expression Regulation, Neoplastic; Hematologic Neoplasms; Histone Deacetylase Inhibitors; Histone Deacetylases; Histones; Humans; Hydroxamic Acids; Mutation; Nucleosomes; Transcription, Genetic; Vorinostat	2008
Therapeutic epigenetics: an emerging clinical approach to hematologic malignancies. Clinical advances in hematology & oncology : H&O, 2005, Volume: 3, Issue:3 Suppl 1 Topics: Azacitidine; Decitabine; DNA Methylation; Epigenesis, Genetic; Hematologic Neoplasms; Histone Deacetylase Inhibitors; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes	2005
Epigenomics in hematopoietic transplantation: novel treatment strategies. Epigenomics, 2011, Volume: 3, Issue:5 Topics: Azacitidine; Decitabine; DNA (Cytosine-5-)-Methyltransferases; Epigenomics; Graft vs Host Disease; Graft vs Leukemia Effect; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Histone Deacetylase Inhibitors; Humans; Immune Tolerance; Immunologic Factors; T-Lymphocytes, Regulatory	2011
Inhibitors of DNA methylation in the treatment of hematological malignancies and MDS. Clinical immunology (Orlando, Fla.), 2003, Volume: 109, Issue:1 Topics: Acetylation; Azacitidine; Cytidine; Decitabine; DNA Methylation; Hematologic Neoplasms; Histones; Humans; Leukemia, Myeloid; Myelodysplastic Syndromes	2003
DNA methylation in haematological malignancies: the role of decitabine. Expert opinion on investigational drugs, 2003, Volume: 12, Issue:12 Topics: Animals; Antimetabolites, Antineoplastic; Azacitidine; Clinical Trials as Topic; Decitabine; DNA Methylation; Hematologic Neoplasms; Humans; Leukemia	2003
Decitabine: development of a DNA methyltransferase inhibitor for hematological malignancies. Current opinion in investigational drugs (London, England : 2000), 2003, Volume: 4, Issue:12 Topics: Animals; Azacitidine; Clinical Trials as Topic; Decitabine; DNA Modification Methylases; Enzyme Inhibitors; Hematologic Neoplasms; Humans	2003
Demethylation of DNA by decitabine in cancer chemotherapy. Expert review of anticancer therapy, 2004, Volume: 4, Issue:4 Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cell Cycle; Cell Differentiation; Decitabine; DNA Methylation; Gene Expression Regulation, Neoplastic; Gene Silencing; Hematologic Neoplasms; Humans	2004
Epigenetic treatment of hematopoietic malignancies: in vivo targets of demethylating agents. Seminars in oncology, 2005, Volume: 32, Issue:5 Topics: Antigens, Neoplasm; Antineoplastic Agents; Azacitidine; Cell Cycle Proteins; Cyclin-Dependent Kinase Inhibitor p15; Decitabine; DNA; DNA Methylation; DNA Modification Methylases; Epigenesis, Genetic; Gene Silencing; Hematologic Neoplasms; Herpesvirus 4, Human; Humans; Leukemia, Myeloid, Acute; Membrane Proteins; Models, Genetic; Neoplasms; Time Factors; Tumor Suppressor Proteins	2005
Inhibitors of DNA methylation: beyond myelodysplastic syndromes. Nature clinical practice. Oncology, 2005, Volume: 2 Suppl 1 Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Decitabine; DNA Modification Methylases; Hematologic Neoplasms; Humans; Leukemia	2005
DNA methyltransferases as targets for cancer therapy. Drugs of today (Barcelona, Spain : 1998), 2007, Volume: 43, Issue:6 Topics: Antineoplastic Agents; Azacitidine; Decitabine; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; Epigenesis, Genetic; Female; Gene Expression Regulation; Gene Silencing; Hematologic Neoplasms; Humans; Leukemia, Myeloid; Male; Myelodysplastic Syndromes; Transcriptional Activation	2007
Decitabine and its role in the treatment of hematopoietic malignancies. Leukemia & lymphoma, 2007, Volume: 48, Issue:8 Topics: Animals; Antimetabolites, Antineoplastic; Azacitidine; Decitabine; DNA Methylation; DNA Modification Methylases; Hematologic Neoplasms; Humans	2007
The use of hypomethylating agents in the treatment of hematologic malignancies. Leukemia & lymphoma, 2007, Volume: 48, Issue:9 Topics: Antimetabolites, Antineoplastic; Azacitidine; Clinical Trials as Topic; Decitabine; DNA Methylation; Hematologic Neoplasms; Histone Deacetylase Inhibitors; Humans; Prognosis; Promoter Regions, Genetic; Quality of Life	2007
Hematologic malignancies: an opportunity for targeted drug therapy. The oncologist, 2001, Volume: 6 Suppl 5 Topics: Angiogenesis Inhibitors; Antimetabolites, Antineoplastic; Azacitidine; DNA, Neoplasm; Erythropoietin; Hematologic Neoplasms; Humans; Recombinant Proteins; Thrombocytopenia	2001

Trials

10 trial(s) available for azacitidine and Hematologic Neoplasms

Article	Year
A Phase 1/2 Study of the Oral Janus Kinase 1 Inhibitors INCB052793 and Itacitinib Alone or in Combination With Standard Therapies for Advanced Hematologic Malignancies. Clinical lymphoma, myeloma & leukemia, 2022, Volume: 22, Issue:7 Topics: Acetonitriles; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Hematologic Neoplasms; Humans; Janus Kinase 1; Janus Kinase Inhibitors; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Pyrazoles; Pyrimidines; Pyrroles	2022
Azacitidine (Vidaza Paediatric drugs, 2023, Volume: 25, Issue:6 Topics: Adult; Azacitidine; Child; Hematologic Neoplasms; Humans; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Juvenile; Myelodysplastic Syndromes; Remission Induction	2023
Phase 1 dose escalation multicenter trial of pracinostat alone and in combination with azacitidine in patients with advanced hematologic malignancies. Cancer, 2017, Dec-15, Volume: 123, Issue:24 Topics: Adult; Age Factors; Aged; Aged, 80 and over; Azacitidine; Benzimidazoles; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Hematologic Neoplasms; Humans; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Maximum Tolerated Dose; Middle Aged; Myelodysplastic Syndromes; Neoplasm Invasiveness; Neoplasm Staging; Patient Safety; Risk Assessment; Sex Factors; Survival Analysis; Treatment Outcome	2017
Pharmacokinetics of different formulations of oral azacitidine (CC-486) and the effect of food and modified gastric pH on pharmacokinetics in subjects with hematologic malignancies. Journal of clinical pharmacology, 2014, Volume: 54, Issue:6 Topics: Administration, Oral; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Capsules; Chemistry, Pharmaceutical; Delayed-Action Preparations; Female; Food-Drug Interactions; Hematologic Neoplasms; Humans; Hydrogen-Ion Concentration; Male; Middle Aged; Stomach; Tablets	2014
A phase I study in patients with solid or hematologic malignancies of the dose proportionality of subcutaneous Azacitidine and its pharmacokinetics in patients with severe renal impairment. Pharmacotherapy, 2014, Volume: 34, Issue:5 Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Dose-Response Relationship, Drug; Female; Hematologic Neoplasms; Humans; Injections, Subcutaneous; Male; Middle Aged; Neoplasms; Renal Insufficiency; Severity of Illness Index; Time Factors	2014
A phase I and pharmacodynamic study of the histone deacetylase inhibitor belinostat plus azacitidine in advanced myeloid neoplasia. Investigational new drugs, 2015, Volume: 33, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B; Azacitidine; Cyclin-Dependent Kinase Inhibitor p15; Cyclin-Dependent Kinase Inhibitor p21; Dose-Response Relationship, Drug; Epigenesis, Genetic; Female; Gene Expression; Hematologic Neoplasms; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Male; Maximum Tolerated Dose; Middle Aged; Sulfonamides; Up-Regulation	2015
Phase 1 dose escalation trial of ilorasertib, a dual Aurora/VEGF receptor kinase inhibitor, in patients with hematologic malignancies. Investigational new drugs, 2015, Volume: 33, Issue:4 Topics: Aged; Aminopyridines; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aurora Kinases; Azacitidine; Female; Hematologic Neoplasms; Humans; Male; Maximum Tolerated Dose; Phenylurea Compounds; Protein Kinase Inhibitors; Receptors, Vascular Endothelial Growth Factor	2015
Early epigenetic changes and DNA damage do not predict clinical response in an overlapping schedule of 5-azacytidine and entinostat in patients with myeloid malignancies. Blood, 2009, Sep-24, Volume: 114, Issue:13 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Benzamides; Cytogenetic Analysis; DNA Damage; Drug Administration Schedule; Epigenesis, Genetic; Female; Hematologic Neoplasms; Humans; Male; Middle Aged; Prognosis; Pyridines; Time Factors	2009
Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in hematopoietic malignancies. Blood, 2004, Mar-01, Volume: 103, Issue:5 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Cell Cycle Proteins; Cell Differentiation; Child; Child, Preschool; Cohort Studies; Cyclin-Dependent Kinase Inhibitor p15; Decitabine; DNA Methylation; DNA Modification Methylases; Dose-Response Relationship, Drug; Female; Gene Silencing; Hematologic Neoplasms; Humans; Karyotyping; Leukemia; Male; Methylation; Middle Aged; Myeloproliferative Disorders; Time Factors; Treatment Outcome; Tumor Suppressor Proteins	2004
Pharmacokinetics of 5-azacitidine administered with phenylbutyrate in patients with refractory solid tumors or hematologic malignancies. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, Jun-10, Volume: 23, Issue:17 Topics: Antimetabolites, Antineoplastic; Azacitidine; Biological Availability; Chromatography, High Pressure Liquid; Drug Administration Schedule; Drug Therapy, Combination; Hematologic Neoplasms; Humans; Metabolic Clearance Rate; Neoplasm Recurrence, Local; Phenylbutyrates	2005

Other Studies

29 other study(ies) available for azacitidine and Hematologic Neoplasms

Article	Year
Inhibition of SUMOylation enhances DNA hypomethylating drug efficacy to reduce outgrowth of hematopoietic malignancies. Leukemia, 2023, Volume: 37, Issue:4 Topics: Azacitidine; Burkitt Lymphoma; Cell Line, Tumor; Decitabine; DNA; Hematologic Neoplasms; Humans; Lymphoma, Large B-Cell, Diffuse; Sumoylation	2023
DNA methyltransferase inhibition overcomes diphthamide pathway deficiencies underlying CD123-targeted treatment resistance. The Journal of clinical investigation, 2019, 11-01, Volume: 129, Issue:11 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cell Line, Tumor; Dendritic Cells; DNA Methylation; Drug Delivery Systems; Female; Hematologic Neoplasms; Humans; Interleukin-3 Receptor alpha Subunit; Leukemia, Myeloid, Acute; Male; Mice; Mice, Nude; Minor Histocompatibility Antigens; Neoplasm Proteins; Recombinant Fusion Proteins; Tumor Suppressor Proteins; Xenograft Model Antitumor Assays	2019
Activation of a Subset of Evolutionarily Young Transposable Elements and Innate Immunity Are Linked to Clinical Responses to 5-Azacytidine. Cancer research, 2020, 06-15, Volume: 80, Issue:12 Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Cohort Studies; DNA Transposable Elements; Drug Resistance, Neoplasm; Endogenous Retroviruses; Female; Gene Expression Regulation, Neoplastic; Hematologic Neoplasms; Humans; Immunity, Innate; Interferon Type I; Male; Middle Aged; Molecular Mimicry; RNA-Seq; Signal Transduction; Up-Regulation	2020
Treatment of human cells with 5-aza-dC induces formation of PARP1-DNA covalent adducts at genomic regions targeted by DNMT1. DNA repair, 2020, Volume: 96 Topics: Antimetabolites, Antineoplastic; Azacitidine; Cells, Cultured; CpG Islands; DNA; DNA (Cytosine-5-)-Methyltransferase 1; DNA Adducts; DNA Methylation; Hematologic Neoplasms; Humans; K562 Cells; Poly (ADP-Ribose) Polymerase-1	2020
Repurposing From Oncology to Cardiology: Low-Dose 5-Azacytidine Attenuates Pathological Cardiac Remodeling in Response to Pressure Overload Injury. Journal of cardiovascular pharmacology and therapeutics, 2021, Volume: 26, Issue:4 Topics: Animals; Azacitidine; Cardiomegaly; DNA Methylation; Drug Repositioning; Electrocardiography; Hematologic Neoplasms; Male; Mice; Mice, Inbred C57BL	2021
Combination of Tagraxofusp and Azacitidine Is an Effective Option for Relapsed Blastic Plasmacytoid Dendritic Cell Neoplasm After Allogeneic Hematopoietic Stem-Cell Transplantation. Clinical lymphoma, myeloma & leukemia, 2021, Volume: 21, Issue:7 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Chemotherapy, Adjuvant; Dendritic Cells; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Male; Neoplasm Recurrence, Local; Recombinant Fusion Proteins; Skin Neoplasms; Treatment Outcome	2021
Daratumumab-based therapy after prior Azacytidine-Venetoclax in an octagenerian female with BPDCN (blastic plasmacytoid dendritic cell neoplasm) - a new perspective. Leukemia & lymphoma, 2021, Volume: 62, Issue:12 Topics: Antibodies, Monoclonal; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Dendritic Cells; Female; Hematologic Neoplasms; Humans; Skin Neoplasms; Sulfonamides	2021
Azacitidine Mitigates Graft-versus-Host Disease via Differential Effects on the Proliferation of T Effectors and Natural Regulatory T Cells In Vivo. Journal of immunology (Baltimore, Md. : 1950), 2017, 05-01, Volume: 198, Issue:9 Topics: Animals; Azacitidine; Cell Proliferation; Cells, Cultured; Cyclin-Dependent Kinase Inhibitor p21; Forkhead Transcription Factors; Graft vs Host Disease; Graft vs Leukemia Effect; Growth Inhibitors; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Interleukin-2 Receptor alpha Subunit; Mice; Mice, Inbred C57BL; Mice, Knockout; Mice, Mutant Strains; Postoperative Complications; T-Lymphocytes, Helper-Inducer; T-Lymphocytes, Regulatory; Up-Regulation	2017
Single agent and synergistic combinatorial efficacy of first-in-class small molecule imipridone ONC201 in hematological malignancies. Cell cycle (Georgetown, Tex.), 2018, Volume: 17, Issue:4 Topics: Activating Transcription Factor 4; Animals; Antineoplastic Agents; Apoptosis; Azacitidine; Boron Compounds; Cell Line, Tumor; Cell Survival; Drug Screening Assays, Antitumor; Drug Synergism; G1 Phase Cell Cycle Checkpoints; Glycine; Hematologic Neoplasms; Heterocyclic Compounds, 4 or More Rings; Humans; Imidazoles; Mice; Mice, SCID; Pyridines; Pyrimidines; Transcription Factor CHOP; Transplantation, Heterologous	2018
Successful Treatment of Hemophagocytic Lymphohistiocytosis Associated with Low-risk Myelodysplastic Syndrome by Azacitidine. Internal medicine (Tokyo, Japan), 2018, Oct-15, Volume: 57, Issue:20 Topics: Aged; Antimetabolites, Antineoplastic; Asian People; Azacitidine; Hematologic Neoplasms; Humans; Lymphohistiocytosis, Hemophagocytic; Lymphoma; Male; Myelodysplastic Syndromes; Treatment Outcome	2018
DNA Methyltransferase Inhibition Promotes Th1 Polarization in Human CD4 Journal of immunology research, 2018, Volume: 2018 Topics: Aged; Aged, 80 and over; Azacitidine; Cell Differentiation; Cell Proliferation; Cell Separation; Cells, Cultured; Decitabine; DNA (Cytosine-5-)-Methyltransferase 1; Female; Flow Cytometry; Forkhead Transcription Factors; Hematologic Neoplasms; Humans; Immunosuppression Therapy; Interferon-gamma; Interleukin-2 Receptor alpha Subunit; Male; Middle Aged; T-Lymphocytes, Regulatory; Th1 Cells	2018
[The safety of decitabine as bridging pretreatment regimen before hematopoietic stem cell transplantation in pediatric hematological malignancies]. Zhonghua nei ke za zhi, 2018, Sep-01, Volume: 57, Issue:9 Topics: Antimetabolites, Antineoplastic; Azacitidine; Child; Clinical Protocols; Decitabine; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Transplantation Conditioning	2018
Maintenance 5-azacytidine therapy by MRD monitoring after allogeneic HSCT in myeloid/lymphoid neoplasms with FGFR1 rearrangement. Bone marrow transplantation, 2019, Volume: 54, Issue:7 Topics: Adult; Allografts; Azacitidine; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Maintenance Chemotherapy; Male; Neoplasm, Residual	2019
Azacitidine salvage therapy for relapse of myeloid malignancies following allogeneic hematopoietic SCT. Bone marrow transplantation, 2014, Volume: 49, Issue:4 Topics: Adolescent; Adult; Aged; Azacitidine; Female; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Retrospective Studies; Salvage Therapy; Transplantation, Homologous; Young Adult	2014
Blastic plasmacytoid dendritic cell neoplasm: the first report of two cases treated by 5-azacytidine. European journal of haematology, 2014, Volume: 93, Issue:1 Topics: Aged; Aged, 80 and over; Azacitidine; Female; Hematologic Neoplasms; Humans; Male	2014
Combination therapy with ruxolitinib plus 5-azacytidine or continuous infusion of low dose cytarabine is feasible in patients with blast-phase myeloproliferative neoplasms. British journal of haematology, 2014, Volume: 167, Issue:5 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Blast Crisis; Female; Hematologic Neoplasms; Humans; Male; Myeloproliferative Disorders; Nitriles; Pyrazoles; Pyrimidines	2014
Genomic and functional analysis of leukemic transformation of myeloproliferative neoplasms. Proceedings of the National Academy of Sciences of the United States of America, 2014, Dec-16, Volume: 111, Issue:50 Topics: Animals; Azacitidine; Benzodioxoles; Blotting, Western; Colony-Forming Units Assay; Decitabine; Exome; Flow Cytometry; Hematologic Neoplasms; High-Throughput Nucleotide Sequencing; Humans; Janus Kinase 2; Leukemia, Myeloid, Acute; Mice; Mutation, Missense; Myeloproliferative Disorders; Nitriles; Purines; Pyrazoles; Pyrimidines; Tumor Suppressor Protein p53	2014
Yin and yang of cytidine deaminase roles in clinical response to azacitidine in the elderly: a pharmacogenetics tale. Pharmacogenomics, 2015, Volume: 16, Issue:17 Topics: Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Cytidine Deaminase; Hematologic Neoplasms; Humans; Male; Pharmacogenetics	2015
Vitamin C increases viral mimicry induced by 5-aza-2'-deoxycytidine. Proceedings of the National Academy of Sciences of the United States of America, 2016, 09-13, Volume: 113, Issue:37 Topics: Apoptosis; Ascorbic Acid; Ascorbic Acid Deficiency; Azacitidine; Cell Proliferation; Decitabine; Dioxygenases; DNA Methylation; DNA-Binding Proteins; Drug Synergism; Endogenous Retroviruses; Enzyme Inhibitors; Female; Hematologic Neoplasms; Humans; Interferons; Male; Methyltransferases; Proto-Oncogene Proteins; RNA, Double-Stranded	2016
Haematological cancer: TP53 mutations sensitize to decitabine. Nature reviews. Clinical oncology, 2017, Volume: 14, Issue:2 Topics: Azacitidine; Decitabine; Genes, p53; Hematologic Neoplasms; Humans; Mutation	2017
The aberrant asynchronous replication - characterizing lymphocytes of cancer patients - is erased following stem cell transplantation. BMC cancer, 2010, May-24, Volume: 10 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aneuploidy; Azacitidine; Cells, Cultured; Child; Child, Preschool; Chromosomes, Human, Pair 17; Chromosomes, Human, Pair 21; Core Binding Factor Alpha 2 Subunit; DNA Modification Methylases; DNA Replication Timing; Enzyme Inhibitors; Epigenesis, Genetic; Female; Hematologic Neoplasms; Humans; In Situ Hybridization, Fluorescence; Lymphocytes; Male; Middle Aged; Stem Cell Transplantation; Time Factors; Transplantation, Homologous; Treatment Outcome; Tumor Suppressor Protein p53; Young Adult	2010
Epigenetic inactivation of the miR-124-1 in haematological malignancies. PloS one, 2011, Apr-22, Volume: 6, Issue:4 Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Azacitidine; Blotting, Western; Cell Line, Tumor; Chromatin Immunoprecipitation; Cyclin-Dependent Kinase 6; Epigenesis, Genetic; Female; Hematologic Neoplasms; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid, Acute; Lymphoma; Lymphoma, Non-Hodgkin; Male; Methylation; MicroRNAs; Middle Aged; Multiple Myeloma; Reverse Transcriptase Polymerase Chain Reaction; Young Adult	2011
HSPB8 is methylated in hematopoietic malignancies and overexpression of HSPB8 exhibits antileukemia effect. Experimental hematology, 2012, Volume: 40, Issue:1 Topics: Azacitidine; Decitabine; DNA Methylation; Gene Expression Regulation, Neoplastic; Heat-Shock Proteins; Hematologic Neoplasms; HL-60 Cells; Humans; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lymphoma; Molecular Chaperones; Protein Serine-Threonine Kinases; Tumor Cells, Cultured	2012
Latexin is down-regulated in hematopoietic malignancies and restoration of expression inhibits lymphoma growth. PloS one, 2012, Volume: 7, Issue:9 Topics: Animals; Antigens; Antigens, CD34; Apoptosis; Azacitidine; Cell Line, Tumor; Cell Proliferation; CpG Islands; DNA Methylation; Down-Regulation; Female; Gene Expression Regulation, Leukemic; Gene Expression Regulation, Neoplastic; Hematologic Neoplasms; Humans; Indicators and Reagents; Lymphoma; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Promoter Regions, Genetic	2012
Hypermethylation of death-associated protein (DAP) kinase CpG island is frequent not only in B-cell but also in T- and natural killer (NK)/T-cell malignancies. Cancer science, 2003, Volume: 94, Issue:1 Topics: Antibodies, Monoclonal; Apoptosis; Apoptosis Regulatory Proteins; Azacitidine; B-Lymphocytes; Calcium-Calmodulin-Dependent Protein Kinases; CpG Islands; Death-Associated Protein Kinases; Decitabine; DNA Methylation; Enzyme Induction; fas Receptor; Gene Expression Regulation, Neoplastic; Hematologic Neoplasms; Humans; Jurkat Cells; Killer Cells, Natural; Leukemia-Lymphoma, Adult T-Cell; Lymphoma, B-Cell; Lymphoma, T-Cell; Neoplasm Proteins; Neoplastic Stem Cells; Promoter Regions, Genetic; Reverse Transcriptase Polymerase Chain Reaction; T-Lymphocytes	2003
5-Aza-2'-deoxycytidine (decitabine) treatment of hematopoietic malignancies: a multimechanism therapeutic approach? Blood, 2003, Jun-01, Volume: 101, Issue:11 Topics: Aged; Aged, 80 and over; Azacitidine; Decitabine; DNA Methylation; Female; Gene Expression Regulation; Hematologic Neoplasms; Humans; Male; Middle Aged; Neoplasm Proteins	2003
Mutations and aberrant DNA methylation of the PROX1 gene in hematologic malignancies. Genes, chromosomes & cancer, 2003, Volume: 38, Issue:1 Topics: Azacitidine; Base Sequence; CpG Islands; DNA Methylation; Exons; Gene Expression Regulation, Neoplastic; Hematologic Neoplasms; HL-60 Cells; Homeodomain Proteins; Humans; Introns; Jurkat Cells; K562 Cells; Lymph Nodes; Molecular Sequence Data; Mutation; Polymerase Chain Reaction; Sulfites; Tumor Cells, Cultured; Tumor Suppressor Proteins; U937 Cells	2003
Methylation of the MLH1 gene in hematological malignancies. Oncology reports, 2005, Volume: 14, Issue:1 Topics: Adaptor Proteins, Signal Transducing; Antimetabolites, Antineoplastic; Azacitidine; Carrier Proteins; Cell Line, Tumor; DNA Methylation; DNA-Binding Proteins; DNA, Neoplasm; Gene Expression Regulation, Neoplastic; Hematologic Neoplasms; Humans; Jurkat Cells; Lymphoma, T-Cell; MutL Protein Homolog 1; MutS Homolog 2 Protein; Neoplasm Proteins; Nuclear Proteins; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Promoter Regions, Genetic; Proto-Oncogene Proteins; Reverse Transcriptase Polymerase Chain Reaction; RNA, Neoplasm	2005
DNA methylation in the treatment of hematologic malignancies. Clinical advances in hematology & oncology : H&O, 2005, Volume: 3, Issue:9 Topics: Azacitidine; Decitabine; DNA Methylation; Enzyme Inhibitors; Hematologic Neoplasms; Humans	2005